advertisement
Abstract #8862 Published in IGR 5-1
A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study
Parrish RK 2nd; Palmberg P; Wang-Pui Sheu MA; XLT STUDY GROUPAmerican Journal of Ophthalmology 2003; 135: 688-703
PURPOSE: To Internet Advance publication at ajo.com Feb 13, 2003. Compare the intraocular pressure (IOP)-lowering effect and safety of latanoprost, bimatoprost, and travoprost in patients with open-angle glaucoma (OAG) or ocular hypertension (OH). DESIGN: Interventional study. METHODS: This 12-week, randomized, parallel-group study was conducted at 45 US sites. previously treated patients with OAG or OH and an IOP =23 mmHg in one or both eyes after washout received either latanoprost 0.005%, bimatoprost 0.03%, or travoprost 0.004% once daily in the evening. At baseline and after 6 and 12 weeks of therapy, masked evaluators measured IOP in triplicate at 8:00 am, 12 noon, 4:00 pm, and 8:00 pm, and masked investigators graded conjunctival hyperemia before the 8:00 am IOP measurement. The primary efficacy outcome measure was change between baseline and Week 12 in the 8:00 am IOP (time of peak drug effect). RESULTS: In all, 410 of 411 randomized patients were included in intent-to-treat analyses (latanoprost, 136; bimatoprost, 136; travoprost, 138). Baseline mean 8:00 am IOP levels were similar (P = .772); by week 12, reductions were observed in all 3 groups (P < .001 for each). Adjusted (ANCOVA) reductions in mean IOP at 8:00 am were similar (P = .128) as were those at 12 noon, 4:00 pm, and 8:00 pm. Fewer latanoprost-treated patients reported ocular adverse events (P < .001, latanoprost vs bimatoprost), fewer reported hyperemia (P = .001, latanoprost vs bimatoprost), and average hyperemia scores were lower at week 12 (P = .001, latanoprost vs bimatoprost). CONCLUSIONS: Latanoprost, bimatoprost, and travoprost were comparable in their ability to reduce IOP in OAG and OH patients. Latanoprost exhibited greater ocular tolerability. Research sponsored by Pharmacia Corporation.
Bascom Palmer Eye Institute Miami, Florida, USA & Pharmacia Corporation, Peapack, New Jersey, USA (W.P.S.)
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
